2034年全球醫藥建模軟體市場預測－按組件、部署類型、作業系統、企業規模、採購模式、應用、最終用戶和地區分類的分析

根據 Stratistics MRC 的數據，預計到 2026 年，全球藥物發現建模軟體市場規模將達到 104 億美元，並在預測期內以 10.5% 的複合年成長率成長，到 2034 年將達到 231 億美元。

藥物發現建模軟體是指利用演算法和模擬來預測、分析和最佳化藥物發現和藥物開發各個方面的計算工具。這些程序有助於理解分子間相互作用、藥物動力學和藥物-標靶相互作用。透過模擬和建模生物系統、化學結構和藥物行為，它們支持潛在候選藥物的設計、篩檢和最佳化，從而提高藥物研發過程的效率和成功率。

根據美國藥品製造商協會（PhRMA）的數據，一種藥物的平均研發成本為 26 億美元。

新治療方法的需求日益成長

複雜疾病的日益普遍和不斷變化的治療需求，使得創新有效的治療方法變得特別迫切。藥物發現建模軟體能夠探索各種分子結構並進行預測模擬，從而加速有前景的候選藥物的識別和最佳化。這種技術主導的方法不僅加速了藥物發現進程，還支持個人化治療方法的設計，滿足了人們對更精準、更有針對性和更有效治療方法的需求，進而推動了軟體在醫療創新中的重要性及其廣泛應用。

與檢驗和準確性相關的挑戰

確保預測模型的準確性和可靠性需要對實驗數據進行廣泛的檢驗，這通常需要花費大量時間和資源。此外，複雜的生物系統和多樣的藥物-標靶交互作用也為準確度帶來了挑戰，影響軟體的預測能力。難以精確模擬真實世界的複雜性會阻礙軟體的有效性，因此持續改進和檢驗工作至關重要。

人們對基於雲端的分析和數據處理的興趣日益濃厚

雲端平台提供擴充性且經濟高效的基礎設施，能夠處理大量資料集和複雜運算。這種轉變能夠增強協作、加快處理速度並改善對高階建模工具的存取。此外，基於雲端的解決方案有助於與其他應用程式無縫整合，並支援全球研究人員之間的即時資料共用。順應此趨勢不僅可以簡化工作流程，還能促進創新，使機構能夠利用最尖端科技推動藥物發現和開發，同時最佳化成本和資源利用。

對資料隱私和安全的擔憂

資料隱私和安全問題對藥物研發建模軟體市場構成重大威脅。藥物研發中病患資料的敏感性和機密資訊的複雜性，引發了人們對潛在資料外洩、未授權存取或濫用的擔憂。安全漏洞會削弱信任，降低軟體採用率，並阻礙製藥公司與軟體供應商之間的合作。此外，諸如GDPR和HIPAA等嚴格法規對醫療保健資料的處理提出了嚴格的標準，這加大了軟體開發商確保合規性的壓力。

新冠疫情的影響：

新冠疫情加速了藥物建模軟體的普及應用，強化了其在遠距藥物研發和虛擬臨床試驗中的作用。這促使人們更加依賴預測分析和計算方法進行快速藥物設計和拓展適應症，從而能夠更快地應對這場新的健康危機。然而，研究和臨床活動的中斷暫時影響了市場成長。儘管如此，疫情凸顯了此類軟體的重要性，促進了創新，並鞏固了其在敏捷遠距藥物研發流程中的關鍵作用。

在預測期內，醫院和醫療保健提供者細分市場預計將是最大的。

由於醫院和醫療服務提供者擴大使用先進軟體來製定個人化治療策略、預測藥物療效和最佳化治療方案，預計該領域將推動藥物研發建模軟體市場的發展。專注於精準醫療的醫院和醫療服務提供者正在利用藥物研發建模軟體來輔助臨床決策並改善患者照護效果。此外，這些工具與電子健康記錄的無縫整合也增強了該領域的競爭優勢。

預計在預測期內，藥物發現和開發領域將呈現最高的複合年成長率。

由於對新型療法的需求持續成長，藥物發現和開發領域預計將迎來顯著成長。藥物研發公司越來越依賴先進的建模軟體來加速潛在候選藥物的識別、設計和最佳化。此外，人工智慧 (AI) 和機器學習的整合有望進一步提高效率，並推動藥物建模軟體市場這一細分領域的顯著成長。

市佔率最大的地區：

北美地區憑藉其強大的製藥和生物技術產業，預計將引領製藥建模軟體市場的發展。該地區擁有大量的研發投入、先進的醫療基礎設施以及眾多行業巨頭的強大影響力。此外，對創新和技術應用的高度重視，以及對個人化醫療和精準藥物研發的強勁需求，正在推動先進建模軟體的應用。這些因素，再加上有利的法規結構和重視新技術早期應用的文化，使北美在製藥建模軟體市場佔據主導地位。

複合年成長率最高的地區：

亞太地區醫藥建模軟體市場預計將迎來顯著成長，這主要得益於該地區快速發展的製藥和生技產業，以及研發投入的不斷增加。此外，龐大的病患群體可用於臨床試驗，以及精準醫療日益受到重視，這些因素都在加速醫藥建模軟體的應用。同時，不斷完善的醫療基礎設施、技術的進步以及政府的支持性舉措，也進一步推動了該地區的市場成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

• 企業概況
  • 對其他市場參與者（最多 3 家公司）進行全面分析
  • 對主要公司進行SWOT分析（最多3家公司）
• 區域細分
  • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
• 競爭性標竿分析
  • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

• 概括
• 相關利益者
• 調查範圍
• 調查方法
• 研究材料

第3章 市場趨勢分析

• 促進因素
• 抑制因子
• 機會
• 威脅
• 應用分析
• 最終用戶分析
• 新冠疫情的感染疾病

第4章：波特五力分析

• 供應商的議價能力
• 買方的議價能力
• 替代品的威脅
• 新進入者的威脅
• 競爭公司之間的競爭

第5章 全球製藥建模軟體市場：依組件分類

• 軟體
• 資料庫

第6章 全球製藥建模軟體市場：依部署方式分類

• 基於雲端的
• 混合型
• 現場

第7章 全球製藥建模軟體市場：依作業系統分類

• Windows
• Linux
• Mac OS
• 其他作業系統

第8章 全球製藥建模軟體市場：依公司規模分類

• 公司規模大
• 小型企業規模

第9章：全球製藥建模軟體市場：依購買模式分類

• 訂閱制
• 一次許可證

第10章 全球製藥建模軟體市場：依應用領域分類

• 細胞模擬
• 化學資訊學
• 疾病建模
• 藥物發現與開發
• 基因序列分析
• 圖形分子建模
• 醫學影像診斷
• 蛋白質建模
• 其他用途

第11章 全球製藥建模軟體市場：依最終用戶分類

• 受託研究機構（CRO）
• 製藥和生物技術公司
• 醫院和醫療保健機構
• 其他最終用戶

第10章 全球製藥建模軟體市場：按地區分類

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙
  • 其他歐洲國家
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 紐西蘭
  • 韓國
  • 其他亞太國家
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 其他南美國家
• 中東和非洲
  • 沙烏地阿拉伯
  • UAE
  • 卡達
  • 南非
  • 其他中東和非洲國家

第11章 主要發展

• 合約、夥伴關係、合作關係、合資企業
• 收購與併購
• 新產品發布
• 業務拓展
• 其他關鍵策略

第12章：公司簡介

• Acellera
• Biovia
• Certara
• Chemical Computing Group
• Collaborative Drug Discovery, Inc.
• Cresset
• Genedata AG
• Insilico Medicine
• Instinctools GmbH
• Leadscope, Inc.
• Molecular Networks GmbH
• Nimbus Therapeutics
• Numerate, Inc.
• OpenEye Scientific Software
• Optibrium Ltd.
• Pharmacelera
• Physiomics plc
• Schrodinger, Inc.
• Simulations Plus, Inc.

According to Stratistics MRC, the Global Drug Modeling Software Market is accounted for $10.4 billion in 2026 and is expected to reach $23.1 billion by 2034 growing at a CAGR of 10.5% during the forecast period Drug Modeling Software refers to computational tools employing algorithms and simulations to predict, analyze and optimize aspects of drug discovery and development. These programs facilitate the understanding of molecular interactions, pharmacokinetics and drug-target interactions. By simulating and modeling biological systems, chemical structures and drug behavior, they aid in designing, screening and optimizing potential drug candidates, enhancing the efficiency and success rates of pharmaceutical research and development processes.

According to the Pharmaceutical Research and Manufacturers of America, a successful drug's research and development cost an average of US$2.6 BN.

Market Dynamics:

Driver:

Growing need for novel treatments

With an increasing prevalence of complex diseases and evolving therapeutic requirements, there's a pressing need for innovative and effective treatments. Drug modeling software enables the exploration of diverse molecular structures and predictive simulations, expediting the identification and optimization of potential drug candidates. This technology-driven approach not only accelerates the discovery process but also aids in designing tailored therapies, meeting the demand for more precise, targeted and efficacious treatments, consequently propelling the software's significance and adoption in advancing healthcare innovation.

Restraint:

Validation and precision challenges

Ensuring the accuracy and reliability of predictive models requires extensive validation against experimental data, often demanding substantial time and resources. Additionally, complex biological systems and the diverse interactions between drugs and targets contribute to precision challenges, impacting the software's predictive capabilities. The limitations of accurately replicating real-world complexities hinder the software's effectiveness, necessitating continuous refinement and validation efforts.

Opportunity:

Rising interest in cloud-based analytics and data processing

Cloud platforms offer scalable, cost-effective infrastructure capable of handling vast datasets and complex computations. This shift allows for enhanced collaboration, faster processing speeds and greater accessibility to sophisticated modeling tools. Moreover, cloud-based solutions facilitate seamless integration with other applications and enable real-time data sharing among researchers globally. Embracing this trend not only streamlines workflows but also fosters innovation, empowering organizations to leverage cutting-edge technologies and drive advancements in drug discovery and development while optimizing costs and resource utilization.

Threat:

Data privacy and security concerns

Data privacy and security concerns pose a significant threat to the drug modeling software market. The sensitive nature of patient data and proprietary information in drug development raises apprehensions about potential breaches, unauthorized access or data misuse. Instances of security lapses could erode trust, impact adoption rates, and hinder collaboration between pharmaceutical entities and software providers. Moreover, stringent regulations like GDPR and HIPAA impose rigorous standards for handling healthcare data, augmenting the pressure on software developers to ensure compliance.

Covid-19 Impact:

The COVID-19 pandemic accelerated the adoption of drug modeling software, intensifying its role in remote drug development and virtual clinical trials. It prompted a heightened reliance on predictive analytics and computational methods for rapid drug design and repurposing, facilitating faster responses to emerging health crises. However, disruptions in research and clinical activities temporarily affected market growth. Yet, the pandemic underscored the software's criticality, spurring innovation and reinforcing its pivotal role in agile and remote drug development processes.

The hospitals & healthcare providers segment is expected to be the largest during the forecast period

The hospitals and healthcare providers segment is anticipated to lead the drug modeling software market due to its increasing leverage of advanced software for personalized treatment strategies, drug efficacy predictions and treatment optimization. With a focus on precision medicine, hospitals and healthcare providers utilize drug modeling software for clinical decision support, enhancing patient care outcomes. Additionally, the integration of these tools into electronic health records facilitates seamless implementation, contributing to the segment's dominance.

The drug discovery and development segment is expected to have the highest CAGR during the forecast period

The drug discovery and development segment is poised for significant growth owing to the continuous surge in demand for novel therapeutics. Drug developers increasingly rely on advanced modeling software to expedite the identification, design and optimization of potential drug candidates. Additionally, the integration of artificial intelligence and machine learning further enhances efficiency, driving the substantial anticipated growth of this segment within the drug modeling software market.

Region with largest share:

North America is anticipated to lead the drug modeling software market due to its robust pharmaceutical and biotech sectors. The region boasts significant R&D investments, advanced healthcare infrastructure and a strong presence of major industry players. Moreover, the region's emphasis on innovation and technology adoption, coupled with a high demand for personalized medicine and precision drug development, drives the use of sophisticated modeling software. These factors, combined with supportive regulatory frameworks and a culture of early adoption of novel technologies, position North America to dominate the drug modeling software market.

Region with highest CAGR:

Asia Pacific is poised for substantial growth in the drug modeling software market due to the region's burgeoning pharmaceutical and biotech industries, coupled with increasing R&D investments. Additionally, the presence of a vast patient pool for clinical trials and a growing emphasis on precision medicine foster the adoption of drug modeling software. Moreover, expanding healthcare infrastructure, technological advancements and supportive government initiatives propel growth in this region.

Key players in the market

Some of the key players in drug modeling software market include Acellera, Biovia, Certara, Chemical Computing Group, Collaborative Drug Discovery, Inc., Cresset, Genedata AG, Insilico Medicine, Instinctools GmbH, Leadscope, Inc., Molecular Networks GmbH, Nimbus Therapeutics, Numerate, Inc., OpenEye Scientific Software, Optibrium Ltd., Pharmacelera, Physiomics plc, Schrodinger, Inc. and Simulations Plus, Inc.

Key Developments:

In May 2023, Cresset announced the latest release of molecular modeling platform that delivers improved efficiencies for small molecule discovery therefore Flare V7. This helps the organisation developing more revenue.

In May 2023, Fujitsu launched the Biodrug Design Accelerator platform to increase peptide drug discovery research. This platform helps peptide drug discovery scientists in pharmaceutical industries to speed up and increases the efficiency of peptide drug development, especially through the cycles "design, make, test, analyze" (DMTA), ultimately allowing faster and informed design of peptide drug candidates and effective communication among scientists about synthesis and testing.

In February 2023, Accenture has made a strategic investment, through Accenture Ventures, in Ocean Genomics, a technology and AI company that has developed advanced computational platforms to assist biopharma companies to discover and develop more effective diagnostics and therapeutics.

Components Covered:

• Software
• Database

Deployments Covered:

• Cloud Based
• Hybrid-Based
• On-Premises

Operating Systems Covered:

• Windows
• Linux
• Mac Os
• Other Operating Systems

Enterprise Sizes Covered:

• Large Enterprise Size
• Small & Medium Enterprise Size

Purchasing Models Covered:

• Subscription Based
• One-Time License

Applications Covered:

• Cellular Simulation
• Cheminformatics
• Disease Modeling
• Drug Discovery and Development
• Gene Sequence Analysis
• Graphical Molecular Modeling
• Medical Imaging
• Protein Modeling
• Other Applications

End Users Covered:

• Contract Research Organizations (CROs)
• Pharmaceutical & Biotechnology Companies
• Hospitals & Healthcare Providers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Drug Modeling Software Market, By Component

• 5.1 Introduction
• 5.2 Software
• 5.3 Database

6 Global Drug Modeling Software Market, By Deployment

• 6.1 Introduction
• 6.2 Cloud Based
• 6.3 Hybrid-Based
• 6.4 On-Premises

7 Global Drug Modeling Software Market, By Operating System

• 7.1 Introduction
• 7.2 Windows
• 7.3 Linux
• 7.4 Mac Os
• 7.5 Other Operating Systems

8 Global Drug Modeling Software Market, By Enterprise Size

• 8.1 Introduction
• 8.2 Large Enterprise Size
• 8.3 Small & Medium Enterprise Size

9 Global Drug Modeling Software Market, By Purchasing Model

• 9.1 Introduction
• 9.2 Subscription Based
• 9.3 One-Time License

10 Global Drug Modeling Software Market, By Application

• 10.1 Introduction
• 10.2 Cellular Simulation
• 10.3 Cheminformatics
• 10.4 Disease Modeling
• 10.5 Drug Discovery and Development
• 10.6 Gene Sequence Analysis
• 10.7 Graphical Molecular Modeling
• 10.8 Medical Imaging
• 10.9 Protein Modeling
• 10.10 Other Applications

11 Global Drug Modeling Software Market, By End User

• 11.1 Introduction
• 11.2 Contract Research Organizations (CROs)
• 11.3 Pharmaceutical & Biotechnology Companies
• 11.4 Hospitals & Healthcare Providers
• 11.5 Other End Users

10 Global Drug Modeling Software Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Acellera
• 12.2 Biovia
• 12.3 Certara
• 12.4 Chemical Computing Group
• 12.5 Collaborative Drug Discovery, Inc.
• 12.6 Cresset
• 12.7 Genedata AG
• 12.8 Insilico Medicine
• 12.9 Instinctools GmbH
• 12.10 Leadscope, Inc.
• 12.11 Molecular Networks GmbH
• 12.12 Nimbus Therapeutics
• 12.13 Numerate, Inc.
• 12.14 OpenEye Scientific Software
• 12.15 Optibrium Ltd.
• 12.16 Pharmacelera
• 12.17 Physiomics plc
• 12.18 Schrodinger, Inc.
• 12.19 Simulations Plus, Inc.

List of Tables

• Table 1 Global Drug Modeling Software Market Outlook, By Region (2023-2034) ($MN)
• Table 2 Global Drug Modeling Software Market Outlook, By Component (2023-2034) ($MN)
• Table 3 Global Drug Modeling Software Market Outlook, By Software (2023-2034) ($MN)
• Table 4 Global Drug Modeling Software Market Outlook, By Database (2023-2034) ($MN)
• Table 5 Global Drug Modeling Software Market Outlook, By Deployment (2023-2034) ($MN)
• Table 6 Global Drug Modeling Software Market Outlook, By Cloud Based (2023-2034) ($MN)
• Table 7 Global Drug Modeling Software Market Outlook, By Hybrid-Based (2023-2034) ($MN)
• Table 8 Global Drug Modeling Software Market Outlook, By On-Premises (2023-2034) ($MN)
• Table 9 Global Drug Modeling Software Market Outlook, By Operating System (2023-2034) ($MN)
• Table 10 Global Drug Modeling Software Market Outlook, By Windows (2023-2034) ($MN)
• Table 11 Global Drug Modeling Software Market Outlook, By Linux (2023-2034) ($MN)
• Table 12 Global Drug Modeling Software Market Outlook, By Mac Os (2023-2034) ($MN)
• Table 13 Global Drug Modeling Software Market Outlook, By Other Operating Systems (2023-2034) ($MN)
• Table 14 Global Drug Modeling Software Market Outlook, By Enterprise Size (2023-2034) ($MN)
• Table 15 Global Drug Modeling Software Market Outlook, By Large Enterprise Size (2023-2034) ($MN)
• Table 16 Global Drug Modeling Software Market Outlook, By Small & Medium Enterprise Size (2023-2034) ($MN)
• Table 17 Global Drug Modeling Software Market Outlook, By Purchasing Model (2023-2034) ($MN)
• Table 18 Global Drug Modeling Software Market Outlook, By Subscription Based (2023-2034) ($MN)
• Table 19 Global Drug Modeling Software Market Outlook, By One-Time License (2023-2034) ($MN)
• Table 20 Global Drug Modeling Software Market Outlook, By Application (2023-2034) ($MN)
• Table 21 Global Drug Modeling Software Market Outlook, By Cellular Simulation (2023-2034) ($MN)
• Table 22 Global Drug Modeling Software Market Outlook, By Cheminformatics (2023-2034) ($MN)
• Table 23 Global Drug Modeling Software Market Outlook, By Disease Modeling (2023-2034) ($MN)
• Table 24 Global Drug Modeling Software Market Outlook, By Drug Discovery and Development (2023-2034) ($MN)
• Table 25 Global Drug Modeling Software Market Outlook, By Gene Sequence Analysis (2023-2034) ($MN)
• Table 26 Global Drug Modeling Software Market Outlook, By Graphical Molecular Modeling (2023-2034) ($MN)
• Table 27 Global Drug Modeling Software Market Outlook, By Medical Imaging (2023-2034) ($MN)
• Table 28 Global Drug Modeling Software Market Outlook, By Protein Modeling (2023-2034) ($MN)
• Table 29 Global Drug Modeling Software Market Outlook, By Other Applications (2023-2034) ($MN)
• Table 30 Global Drug Modeling Software Market Outlook, By End User (2023-2034) ($MN)
• Table 31 Global Drug Modeling Software Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
• Table 32 Global Drug Modeling Software Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
• Table 33 Global Drug Modeling Software Market Outlook, By Hospitals & Healthcare Providers (2023-2034) ($MN)
• Table 34 Global Drug Modeling Software Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.